Stay up to date with the latest mentions of Currax in media outlets and interviews. From industry insights to discussions about our mission to improve patient care, this page highlights how Currax is making an impact in healthcare. Explore articles, videos, and news stories that showcase our dedication to innovation and accessibility in weight management and beyond.
Watch the CONTRAVE® (naltrexone HCl/bupropion HCl) TV commercial w/ the track Don't Own Me.
CONTRAVE is a prescription medicine that may help some adults with a BMI ≥ 30, or adults with a BMI ≥ 27 with at least one weight-related medical problem, lose weight & keep the weight off. Use with diet & exercise. It is not known if CONTRAVE changes your risk of, or death due to, heart problems or stroke.
Currax Pharmaceuticals CEO on North Carolina ending obesity drug coverage
George Hampton, president and CEO at Currax Pharmaceuticals, joins 'The Exchange' to discuss the company's obesity drug, the cost of obesity treatment, and more.
Currax is benefitting from weight loss drug demand, says CEO George Hampton
George Hampton, Currax CEO, joins CNBC’s ‘The Exchange’ to discuss the company’s weight loss drugs, how Contrave differs from other offerings, and more.
The obesity population in the U.S. is 95% untreated, says Currax CEO George Hampton
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy.
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
BRENTWOOD, TN, USA, July 23, 2024 / Biotech Newswire / -- Currax Pharmaceuticals LLC (“Currax”) today announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA).
Currax, maker of weight loss drug Contrave, constructs campaign to educate on "food noise"
Though its campaign is an unbranded one, with no outright mention of Currax Pharmaceuticals' weight loss drug Contrave in the ads or on the "Stop the Food Noise" website, the site features multiple links to “get help to control food cravings” and “learn more,” all of which lead straight to Contrave’s own site. (Currax Pharmaceuticals).
Currax Pharmaceuticals CEO says the GLP-1 conversation isn’t one-size-fits-all
Currax Pharmaceuticals CEO George Hampton talks about the ascendance of GLP-1 drugs and how weight loss drugs are changing the obesity narrative.
Why weight-loss drugs aren't covered by insurance
George Hampton, CEO of Currax Pharmaceuticals, joins TheStreet to explain what needs to happen in order for weight loss drugs to become covered by insurance companies.
Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC (“Currax”) announces the first patient screened and accepted into the CONTRAVE® INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3).
Currax Sees Demand for Weight-Loss Drug Contrave Growing
Currax Pharmaceuticals CEO George Hampton talks about the demand for the FDA-approved obesity drug Contrave. Demand is growing fast. He is on "Bloomberg Open Interest." (Source: Bloomberg).
Weight-loss drugs: How low costs, easy access change the game now
Pharmaceutical CEO George Hampton discusses anti-obesity medications and the quickly moving acceleration of their affordability and accessibility.
Contrave mimics diet and exercise: George Hampton
Currax Pharmaceuticals President & CEO George Hampton breaks down the weight loss solution on 'The Claman Countdown.'